Biosyent: Stocks Overvalued by Analyst Consensus on TSX-V (RX)
Biosyent Inc is among the group of overvalued stocks on the TSX Venture Exchange. This means the consensus value for each stock on this list is below its current price.
This report is generated monthly. It provides the close price and target price for these companies along with the number of analysts covering the stock. Also included is the fiscal year for the target price as sometimes these analyst targets are not for the current or even the next fiscal year. Stocks in this category are generally sold to preserve capital.
There may be a number of reasons why a company would be on this list. Companies with a large analyst following with a difference in price versus target are worth exploring in more detail.
| Symbol | Name | Target Year | Close Price | Target Price Mean | Currency | Target Price # Estimates |
|---|---|---|---|---|---|---|
| RCK | Rock Tech Lithium Inc | 2024 | 1.22 | 1 | CAD | 1 |
| RX | Biosyent Inc | 2024 | 8.35 | 8 | CAD | 1 |
All data provided as of November 17, 2023.
More about Biosyent Inc
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.
Biosyent Inc is listed under RX on the TSX Venture Exchange.
Artificial intelligence at Report on Business
Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
